SNRIs explained

What SNRIs are

SNRIs, serotonin-norepinephrine reuptake inhibitors, are a class of antidepressant. The name describes what sets them apart. They act on two chemical messengers in the brain, serotonin and norepinephrine, rather than serotonin alone.

The main SNRIs are venlafaxine (Effexor), desvenlafaxine (Pristiq), duloxetine (Cymbalta), and levomilnacipran (Fetzima). Venlafaxine and duloxetine are the most widely used.

How they work

Serotonin and norepinephrine are chemical messengers that nerve cells use to pass signals to one another. One cell releases a messenger into the small gap between cells, the next cell picks up the signal, and then the releasing cell reabsorbs much of what it sent out. That reabsorption is called reuptake. SNRIs slow the reuptake of both serotonin and norepinephrine, so more of each stays available between cells.

There is one detail worth knowing, because it changes how an SNRI behaves. The two effects do not switch on at the same dose. Venlafaxine in particular acts mostly on serotonin at low doses, so at the bottom of its range it behaves much like an SSRI. Its effect on norepinephrine grows as the dose goes up. So with venlafaxine, the dose does not just change the strength of the medication, it changes the kind of medication it is.

It is worth being honest about the limits of all this. The full picture of how SNRIs ease depression and anxiety is not known. What is clear is that the early change in signaling sets off slower adjustments in the brain over the following weeks, and those slower changes are thought to do the real work. That is why SNRIs take time to help rather than working the day you start them.

How the class developed

SNRIs emerged in the 1990s, after the SSRIs had become established. Venlafaxine was the first to market. The thinking behind the class was straightforward. SSRIs help many people, but not everyone, and some who improve only improve partway. Adding action on a second messenger, norepinephrine, might reach people a serotonin-only medication did not fully help.

There was a second discovery along the way. The norepinephrine action turned out to do more than support mood. Norepinephrine is involved in the body's own pathways for dampening pain signals. That is why some SNRIs, duloxetine especially, became useful for several chronic pain conditions, a role no SSRI fills in the same way.

What they treat

SNRIs are used for major depressive disorder, generalized anxiety disorder, and other anxiety disorders such as panic disorder and social anxiety disorder. As with SSRIs, no single SNRI carries every approval, and prescribers also use them off-label, meaning for a purpose the label doesn't formally list even though evidence and practice support it.

Duloxetine stands apart on the pain side. It is FDA-approved for diabetic peripheral neuropathic pain, which is nerve pain caused by diabetes, for fibromyalgia, and for chronic musculoskeletal pain. The norepinephrine action is part of why an SNRI can ease certain kinds of pain. That makes duloxetine a practical choice when depression or anxiety appears alongside ongoing pain, since one medication can address both.

What they have in common

The medications in this class share a lot, and much of it is shared with SSRIs.

• A timeline of four to six weeks for the fuller effect on mood. Benefit for a pain condition can also take a few weeks to build.
• Early side effects that tend to arrive before the benefits.
• A shared set of common side effects: nausea, sweating, changes in sleep, and sexual side effects.
• Discontinuation symptoms if stopped abruptly, so they need a gradual taper planned with a prescriber.
• The antidepressant boxed warning about a possible increase in suicidal thoughts in people under 25, especially early in treatment.
• A risk of serotonin syndrome, a reaction caused by too much serotonin activity.
• A slightly raised risk of bleeding and bruising, which adds up with NSAIDs, aspirin, or blood thinners.

SNRIs are not addictive in the usual sense. They do not cause cravings or compulsive use, and people do not need rising doses to keep the effect. The body does adjust to them, which is why stopping should be gradual.

How they differ from SSRIs

The defining difference is the added action on norepinephrine. In practice this leads to a few points worth knowing.

SNRIs can raise blood pressure. This effect is dose-related, meaning it is more likely at higher doses, and it is most associated with venlafaxine. A prescriber may check blood pressure before starting an SNRI and during treatment, especially when the dose is on the higher side. SSRIs do not carry this concern in the same way.

As a group, and venlafaxine especially, SNRIs are known for more noticeable discontinuation symptoms than many SSRIs. The short half-life of venlafaxine means its level drops quickly between doses, so missing even a dose or two can bring on dizziness, flu-like feelings, and the brief electrical "brain zap" sensations many people describe. That makes consistent dosing and a careful, gradual taper particularly important.

Beyond that, an SNRI offers a route SSRIs do not. It can help certain chronic pain conditions, and it gives a prescriber a second messenger to work with when a serotonin-only medication has not done enough.

How they differ from each other

The SNRIs are not interchangeable.

Venlafaxine acts more like an SSRI at low doses, with its norepinephrine effect growing at higher doses. It is short-acting and the most notable of the group for discontinuation symptoms.

Desvenlafaxine is closely related to venlafaxine. In fact, the body turns venlafaxine into desvenlafaxine, which is the main active form. Taking desvenlafaxine means taking that active form directly. In practice it often needs less dose adjustment and tends to have fewer drug-metabolism interactions.

Duloxetine carries the chronic pain approvals. It also comes with a caution about rare liver injury, so it is generally avoided in people with significant liver disease or heavy alcohol use.

Levomilnacipran is a newer SNRI used for depression.

How a prescriber chooses one

A prescriber often reaches for an SNRI in one of a few situations. The first is when an SSRI has been tried and has not worked well enough, or has helped only partway, since the added norepinephrine action gives a different angle. The second is when depression or anxiety comes alongside a chronic pain condition, where duloxetine in particular can treat both. Prior response in the person, the side-effect profile that fits best, blood pressure, liver health, and other medications all feed into the choice as well.

An honest point is worth making. SNRIs are not simply stronger or better than SSRIs. They are a different tool, with their own trade-offs, including the blood pressure effect and the more pronounced discontinuation symptoms. Which class fits is a decision to work through with a prescriber.

The medications in this class

• Venlafaxine (Effexor). One of the most widely used SNRIs. It acts more like an SSRI at low doses, with its norepinephrine effect growing at higher doses, and it is best known of the group for discontinuation symptoms.
• Duloxetine (Cymbalta). A widely used SNRI that is also approved for several chronic pain conditions, with a caution about rare liver injury.
• Desvenlafaxine (Pristiq). An SNRI closely related to venlafaxine, the main active form the body makes from it, with simple once-daily dosing.
• Levomilnacipran (Fetzima). A newer SNRI used for depression.

PsychiatryRx has dedicated guides for venlafaxine, duloxetine, and desvenlafaxine, with more detail on uses, side effects, dosing, and what to expect.

Common questions

How do SNRIs differ from SSRIs? SSRIs act on one chemical messenger, serotonin. SNRIs act on two, serotonin and norepinephrine. The two classes are broadly similar in how well they treat depression and anxiety. The norepinephrine action gives SNRIs a second route, which can help certain chronic pain conditions and can reach some people an SSRI did not fully help. It also brings a dose-related blood pressure effect that SSRIs do not.

Why are SNRIs used for pain? Norepinephrine is involved in the body's own pathways for dampening pain signals, separate from its role in mood. By boosting norepinephrine, an SNRI can quiet certain kinds of pain. Duloxetine is FDA-approved for diabetic nerve pain, fibromyalgia, and chronic musculoskeletal pain for this reason.

Are SNRIs harder to stop than SSRIs? As a group they tend to cause more noticeable discontinuation symptoms, and venlafaxine in particular is well known for them. Venlafaxine is short-acting, so its level falls quickly between doses, and missing even a dose or two can bring on dizziness and brain zap sensations. A slow, planned taper handles this. Stopping an SNRI is not dangerous, but it does need care and a prescriber's guidance.

Sources

This guide draws on current prescribing information and public health references. It is reviewed for clinical accuracy and updated as guidance changes.

1. U.S. Food and Drug Administration. Prescribing information.
2. MedlinePlus, U.S. National Library of Medicine.
3. National Institute of Mental Health. Mental health medications.
4. American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder.